Latest & greatest articles for pulmonary embolism

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pulmonary embolism or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pulmonary embolism and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pulmonary embolism

141. Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287)

Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287) Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism | Guidance and guidelines | NICE Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism Technology appraisal guidance [TA287] Published date: 26 June 2013 Share Save Guidance on rivaroxaban (Xarelto) for treating pulmonary embolism and for preventing a further (...) deep vein thrombosis or pulmonary embolism in adults. Guidance development process Is this guidance up to date? . We found nothing new that affects the recommendations in this guidance. Next review: This guidance will be reviewed if there is new evidence that is likely to change the recommendations. Your responsibility The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected

National Institute for Health and Clinical Excellence - Technology Appraisals2013

142. Cohort: Thrombolytic therapy with or without a vena cava filter results in a lower case fatality rate in unstable patients with acute pulmonary embolism

Cohort: Thrombolytic therapy with or without a vena cava filter results in a lower case fatality rate in unstable patients with acute pulmonary embolism Thrombolytic therapy with or without a vena cava filter results in a lower case fatality rate in unstable patients with acute pulmonary embolism | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Thrombolytic therapy with or without a vena cava filter results in a lower case fatality rate in unstable patients with acute pulmonary embolism Article Text Online articles Cohort Thrombolytic therapy with or without

Evidence-Based Medicine (Requires free registration)2013

143. Cohort study: Pretest probability assessment combined with point-of-care D-dimer testing allows primary care physicians to rule out pulmonary embolism

Cohort study: Pretest probability assessment combined with point-of-care D-dimer testing allows primary care physicians to rule out pulmonary embolism Pretest probability assessment combined with point-of-care D-dimer testing allows primary care physicians to rule out pulmonary embolism | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Pretest probability assessment combined with point-of-care D-dimer testing allows primary care physicians to rule out pulmonary embolism Article Text Diagnosis Cohort study Pretest probability assessment combined

Evidence-Based Medicine (Requires free registration)2013

144. Long-term prognostic value of residual pulmonary vascular obstruction at discharge in patients with intermediate- to high-risk pulmonary embolism

Long-term prognostic value of residual pulmonary vascular obstruction at discharge in patients with intermediate- to high-risk pulmonary embolism 23103660 2013 03 04 2013 08 19 2013 03 04 1522-9645 34 9 2013 Mar European heart journal Eur. Heart J. Long-term prognostic value of residual pulmonary vascular obstruction at discharge in patients with intermediate- to high-risk pulmonary embolism. 693-701 10.1093/eurheartj/ehs365 We evaluated prognostic value at 6 months of residual pulmonary (...) vascular obstruction (RPVO) measured before discharge in patients with intermediate- or high-risk pulmonary embolism (PE). Prospective registry including 416 consecutive patients with intermediate- or high-risk PE who survived the acute phase. Patients with previous cardiopulmonary disease were excluded. Perfusion lung scans were performed within 6-8 days after the onset of treatment. Residual pulmonary vascular obstruction was graded as the proportion of the lung not perfused. Primary objective

EvidenceUpdates2012

145. Safe exclusion of pulmonary embolism using the Wells rule and qualitative D-dimer testing in primary care: prospective cohort study.

Safe exclusion of pulmonary embolism using the Wells rule and qualitative D-dimer testing in primary care: prospective cohort study. OBJECTIVE: To validate the use of the Wells clinical decision rule combined with a point of care D-dimer test to safely exclude pulmonary embolism in primary care. DESIGN: Prospective cohort study. SETTING: Primary care across three different regions of the Netherlands (Amsterdam, Maastricht, and Utrecht). PARTICIPANTS: 598 adults with suspected pulmonary embolism (...) in primary care. INTERVENTIONS: Doctors scored patients according to the seven variables of the Wells rule and carried out a qualitative point of care D-dimer test. All patients were referred to secondary care and diagnosed according to local protocols. Pulmonary embolism was confirmed or refuted on the basis of a composite reference standard, including spiral computed tomography and three months' follow-up. MAIN OUTCOME MEASURES: Diagnostic accuracy (sensitivity and specificity), proportion of patients

BMJ2012 Full Text: Link to full Text with Trip Pro

147. Cook celect vena cava filter (Cook Medical Inc.) for prophylaxis and treatment of pulmonary embolism

Cook celect vena cava filter (Cook Medical Inc.) for prophylaxis and treatment of pulmonary embolism Cook celect vena cava filter (Cook Medical Inc.) for prophylaxis and treatment of pulmonary embolism Cook celect vena cava filter (Cook Medical Inc.) for prophylaxis and treatment of pulmonary embolism Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Cook celect (...) vena cava filter (Cook Medical Inc.) for prophylaxis and treatment of pulmonary embolism. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2012 Authors' conclusions Venous thromboembolism (VTE), the formation of blood clots in veins, is a leading cause of disability and death. The syndrome refers to both deep vein thrombosis (DVT) and pulmonary embolism (PE). Each year an estimated 300,000 to 600,000 people in the United States are affected by VTE (1 to 2 per 1000

Health Technology Assessment (HTA) Database.2012

148. Recommendations for the diagnosis and treatment of deep venous thrombosis and pulmonary embolism in pregnancy and the postpartum period

Recommendations for the diagnosis and treatment of deep venous thrombosis and pulmonary embolism in pregnancy and the postpartum period Recommendations for the diagnosis and treatment of deep venous thrombosis and pulmonary embolism in pregnancy and the postpartum period - MCLINTOCK - 2011 - Australian and New Zealand Journal of Obstetrics and Gynaecology - Wiley Online Library , Version of Record online: 6 OCT 2011 Options for accessing this content: If you are a society or association member

Clinical Practice Guidelines Portal2012

149. Pulmonary embolism and deep vein thrombosis.

Pulmonary embolism and deep vein thrombosis. Pulmonary embolism is the third most common cause of death from cardiovascular disease after heart attack and stroke. Sequelae occurring after venous thromboembolism include chronic thromboembolic pulmonary hypertension and post-thrombotic syndrome. Venous thromboembolism and atherothrombosis share common risk factors and the common pathophysiological characteristics of inflammation, hypercoagulability, and endothelial injury. Clinical probability (...) assessment helps to identify patients with low clinical probability for whom the diagnosis of venous thromboembolism can be excluded solely with a negative result from a plasma D-dimer test. The diagnosis is usually confirmed with compression ultrasound showing deep vein thrombosis or with chest CT showing pulmonary embolism. Most patients with venous thromboembolism will respond to anticoagulation, which is the foundation of treatment. Patients with pulmonary embolism should undergo risk stratification

Lancet2012

150. Managing pulmonary embolism using prognostic models: future concepts for primary care

Managing pulmonary embolism using prognostic models: future concepts for primary care 22143233 2012 02 22 2012 04 13 2016 12 15 1488-2329 184 3 2012 Feb 21 CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne CMAJ Managing pulmonary embolism using prognostic models: future concepts for primary care. 305-10 10.1503/cmaj.110213 Geersing Geert-Jan GJ Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands (...) . 2006 Jun 1;354(22):2317-27 16738268 Aged Anticoagulants therapeutic use Female Humans Male Models, Statistical Primary Health Care standards Prognosis Pulmonary Embolism diagnosis drug therapy therapy Risk Factors Secondary Prevention Severity of Illness Index PMC3281155 2011 12 7 6 0 2011 12 7 6 0 2012 4 14 6 0 ppublish 22143233 cmaj.110213 10.1503/cmaj.110213 PMC3281155

EvidenceUpdates2012 Full Text: Link to full Text with Trip Pro

151. Symptomatic in-hospital deep vein thrombosis and pulmonary embolism following hip and knee arthroplasty among patients receiving recommended prophylaxis: a systematic review

Symptomatic in-hospital deep vein thrombosis and pulmonary embolism following hip and knee arthroplasty among patients receiving recommended prophylaxis: a systematic review Symptomatic in-hospital deep vein thrombosis and pulmonary embolism following hip and knee arthroplasty among patients receiving recommended prophylaxis: a systematic review Symptomatic in-hospital deep vein thrombosis and pulmonary embolism following hip and knee arthroplasty among patients receiving recommended (...) or hip, were eligible for inclusion. Eligible inpatients had to be over 18 years of age. Eligible venous thromboembolism prophylactic regimens were low-molecular weight heparin or direct and indirect Xa and IIa factor inhibitors. Deep vein thrombosis had to be confirmed by venography or ultrasonography (with or without impedance plethysmography). Clinical diagnosis of pulmonary embolism had to be confirmed by perfusion/ventilation scintigraphy, pulmonary angiography, spiral computed tomography, or

DARE.2012

152. Systematic review: Thromboprophylaxis in medical inpatients reduces pulmonary embolism, increases the risk of major haemorrhage and does not reduce total mortality, producing questionable net clinical benefit

Systematic review: Thromboprophylaxis in medical inpatients reduces pulmonary embolism, increases the risk of major haemorrhage and does not reduce total mortality, producing questionable net clinical benefit Thromboprophylaxis in medical inpatients reduces pulmonary embolism, increases the risk of major haemorrhage and does not reduce total mortality, producing questionable net clinical benefit | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing (...) to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Thromboprophylaxis in medical inpatients reduces pulmonary embolism, increases the risk of major haemorrhage

Evidence-Based Medicine (Requires free registration)2012

153. Randomised controlled trial: In selected lower risk patients with acute pulmonary embolism, outpatient treatment is not associated with increased risk of adverse outcomes compared with standard inpatient care

Randomised controlled trial: In selected lower risk patients with acute pulmonary embolism, outpatient treatment is not associated with increased risk of adverse outcomes compared with standard inpatient care In selected lower risk patients with acute pulmonary embolism, outpatient treatment is not associated with increased risk of adverse outcomes compared with standard inpatient care | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use (...) of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here In selected lower risk patients with acute pulmonary embolism, outpatient treatment is not associated with increased risk

Evidence-Based Medicine (Requires free registration)2012

154. Pulmonary embolism rule-out criteria (PERC) in pulmonary embolism ? revisited: a systematic review and meta-analysis

Pulmonary embolism rule-out criteria (PERC) in pulmonary embolism ? revisited: a systematic review and meta-analysis Pulmonary embolism rule-out criteria (PERC) in pulmonary embolism — revisited: a systematic review and meta-analysis Pulmonary embolism rule-out criteria (PERC) in pulmonary embolism — revisited: a systematic review and meta-analysis Singh B, Mommer SK, Patricia EJ, Mascarenhas SS, Parsaik AK CRD summary This review concluded that because of their high sensitivity and low (...) negative likelihood ratio, the pulmonary embolism rule-out criteria could be used confidently in settings where patients have low clinical probability. Given the potential overestimation of accuracy, in the included studies, and the calculation of pooled estimates of accuracy in separate analyses, the conclusions should be treated with caution. Authors' objectives To determine the diagnostic performance of pulmonary embolism rule-out criteria (PERC), to rule out pulmonary embolism, without the need

DARE.2012

155. Predictive value of the high-sensitivity troponin T assay and the simplified pulmonary embolism severity index in hemodynamically stable patients with acute pulmonary embolism: a prospective validation study

Predictive value of the high-sensitivity troponin T assay and the simplified pulmonary embolism severity index in hemodynamically stable patients with acute pulmonary embolism: a prospective validation study 22082681 2011 12 13 2012 02 07 2015 11 19 1524-4539 124 24 2011 Dec 13 Circulation Circulation Predictive value of the high-sensitivity troponin T assay and the simplified Pulmonary Embolism Severity Index in hemodynamically stable patients with acute pulmonary embolism: a prospective (...) validation study. 2716-24 10.1161/CIRCULATIONAHA.111.051177 The new, high-sensitivity troponin T (hsTnT) assay may improve risk stratification of normotensive patients with acute pulmonary embolism (PE). We externally validated the prognostic value of hsTnT, and of the simplified Pulmonary Embolism Severity Index (sPESI), in a large multicenter cohort. We prospectively examined 526 normotensive patients with acute PE; of those, 31 (5.9%) had an adverse 30-day outcome. The predefined hsTnT cutoff value

EvidenceUpdates2012

156. Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial.

Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial. 22130488 2012 01 16 2012 02 07 2015 06 16 1474-547X 379 9811 2012 Jan 14 Lancet (London, England) Lancet Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non (...) -inferiority trial. 123-9 10.1016/S0140-6736(11)61505-5 Treatment of pulmonary embolism with low-molecular-weight heparin and vitamin K antagonists, such as warfarin, is not ideal. We aimed to assess non-inferiority of idrabiotaparinux, a reversible longlasting indirect inhibitor of activated factor X, to warfarin in patients with acute symptomatic pulmonary embolism. In our randomised, double-blind, double-dummy, non-inferiority trial, we enrolled adults with objectively documented acute symptomatic

Lancet2012

157. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.

Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. 22449293 2012 04 05 2012 04 12 2015 11 19 1533-4406 366 14 2012 Apr 05 The New England journal of medicine N. Engl. J. Med. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. 1287-97 10.1056/NEJMoa1113572 A fixed-dose regimen of rivaroxaban, an oral factor Xa inhibitor, has been shown to be as effective as standard anticoagulant therapy for the treatment of deep-vein thrombosis, without the need (...) for laboratory monitoring. This approach may also simplify the treatment of pulmonary embolism. In a randomized, open-label, event-driven, noninferiority trial involving 4832 patients who had acute symptomatic pulmonary embolism with or without deep-vein thrombosis, we compared rivaroxaban (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with standard therapy with enoxaparin followed by an adjusted-dose vitamin K antagonist for 3, 6, or 12 months. The primary efficacy outcome was symptomatic

NEJM2012

158. Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)

Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261) Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism | Guidance and guidelines | NICE Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism Technology appraisal guidance [TA261] Published date: 25 July 2012 Share (...) Guidance on rivaroxaban (Xarelto) for treating deep vein thrombosis and preventing a pulmonary embolism or another deep vein thrombosis in adults. Guidance development process Is this guidance up to date? . We found nothing new that affects the recommendations in this guidance. Next review : This guidance will be reviewed if there is new evidence that is likely to affect the recommendations. Your responsibility The recommendations in this guidance represent the view of NICE, arrived at after careful

National Institute for Health and Clinical Excellence - Technology Appraisals2012

159. Are Thrombolytics Indicated for Pulmonary Embolism?

Are Thrombolytics Indicated for Pulmonary Embolism? DEFINE_ME_WA This site requires Cookies to be enabled to function. Please ensure Cookies are turned on and then re-visit the desired page.

Annals of Emergency Medicine Systematic Review Snapshots2012

160. Can selected patients with newly diagnosed pulmonary embolism be safely treated without hospitalization? A systematic review

Can selected patients with newly diagnosed pulmonary embolism be safely treated without hospitalization? A systematic review Can selected patients with newly diagnosed pulmonary embolism be safely treated without hospitalization? A systematic review Can selected patients with newly diagnosed pulmonary embolism be safely treated without hospitalization? A systematic review Vinson DR, Zehtabchi S, Yealy DM CRD summary This generally well-conducted review concluded that data on exclusive (...) outpatient management of acute symptomatic pulmonary embolism were limited but that the existing evidence supported the feasibility and safety of this approach in carefully selected low-risk patients. The authors acknowledged that the available evidence was limited. The conclusion is reflective of the evidence presented. Authors' objectives To assess the safety of initial outpatient management of patients with newly diagnosed pulmonary embolism and their demographics, comorbidities, risk stratification

DARE.2012